Skip to content

    Sumitomo Chemi.

    SUMICHEMGood
    Chemicals·28 Oct 2025
    Management Summary

    Sumitomo Chemical India delivered a resilient H1 FY26 performance despite a challenging Q2 marked by extreme weather conditions that curtailed domestic agrochemical applications. While Q2 volumes were hit by excessive rains, the company maintained pricing discipline and gross margins (43.1%). Management remains optimistic about the Rabi season due to full reservoirs and is accelerating its 'China+1' strategy through significant capex plans at Dahej and Tarapur.

    Highlights

    7

    • H1 FY26 Revenue grew 9% YoY to ₹1,987 crores, while PAT increased 11% YoY to ₹356 crores.

    • Q2 FY26 Revenue declined 6% YoY to ₹930 crores due to erratic and excessive rainfall impacting spraying operations.

    • EBITDA for H1 FY26 stood at ₹437 crores, up 8% YoY, with margins maintained at 22.0%.

    • Cash and cash equivalents reached a robust ₹2,089 crores as of September 30, 2025.

    • Net working capital days improved by 7 days YoY to 55 days, driven by better receivable collections.

    • Domestic business grew 11% YoY in H1, contributing 85% of total revenue, while exports degrew 4%.

    • Management announced a potential ₹500-600 crore capex for the Dahej site over the next 5 years.

    Concerns

    1

    • Climatic Volatility

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹930 Cr-5.8%YoY
    2. 02EBITDA Margin23.4%
    3. 03PAT₹178 Cr-7.7%YoY
    4. 04Gross Margin43.1%
    5. 05Cash and Cash Equivalents₹2,089 Cr

    Segment breakdown

    Revenue ContributionH1 Growth
    Domestic Agrochemicals85%11%
    Exports15%-4%
    Heatmap· 2 shared metrics

    Guidance & targets

    5
    CategoryTargetPriority
    Capex
    Dahej Greenfield Expansion
    ₹500-600 crores
    		Medium
    Capex
    Dahej Phase 1 Investment
    ₹250-300 crores
    		Medium
    Capex
    Tarapur Excalia Max Facility
    ₹8-10 crores
    		High
    Revenue
    New Product Revenue Contribution
    8-10%
    		High
    Capacity
    Dahej Revenue Commencement
    CY 2028
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Climatic Volatility

    Excessive and erratic rainfall in Q2 prevented farmers from spraying, leading to volume contraction. — Management acknowledged

    high

    Regulatory Disruption in Biostimulants

    New licensing requirements halted sales of several biostimulant products for nearly a full quarter. — Both acknowledged

    medium

    Export Market Softness (Latin America/Africa)

    Inventory liquidation in Brazil and shipment deferrals in Africa impacted H1 export performance. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific revenue figures for newly launched products (Lentigo/Excalia Max) were withheld as 'too early'.

    Q&A highlights

    3

    “We absolutely do not try to dump the material in the market to have a performance of one month or one quarter... our primary aim is to maintain the margins or improve the margins and top line comes after that.”

    Management clarifies their strategy of prioritizing profitability and channel health over aggressive top-line growth through 'dumping'.

    asked by Rohan Jain, Blue River Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Weather Disrupts Q2 Spraying Window

    The second quarter was severely impacted by an unusual rainfall pattern, with a dry start to July followed by continuous rain through September. This prevented farmers from entering fields for spraying operations, leading to a 6% YoY revenue decline in Q2 to ₹930 crores. Despite this, management highlighted that they did not see sales returns, indicating that inventory was liquidated rather than returned to the company.

    02

    Strategic Capex Pivot at Dahej and Tarapur

    Sumitomo is aggressively expanding its manufacturing footprint to serve as a global hub for its Japanese parent. The company plans to invest ₹500-600 crores at Dahej over 5 years, with Phase 1 (₹250-300 crores) expected to start generating revenue by CY 2028. Additionally, ₹8-10 crores is being invested at Tarapur to localize the production of the patented fungicide Excalia Max by March 2027, which will eliminate the need for imports from Japan.

    03

    New Product Traction and Speciality Mix

    New launches like Lentigo (rice herbicide) and Excalia Max are performing ahead of internal targets. Management expects new products to contribute 8-10% of annual revenue. The speciality segment remains a core focus, maintaining a 28-30% revenue share. The company also successfully launched CTPR formulations, which have seen strong adoption in the off-patent segment.

    04

    Export Headwinds and China Competition

    Export revenue degrew 4% in H1, primarily due to a 33% decline in sales to South America as Brazil liquidated existing inventory. However, management noted that R&D-led process improvements have allowed them to match Chinese pricing in generic exports while maintaining margins. They expect the Africa export season to pick up in late December or early January.

    05

    Robust Balance Sheet and Cash Deployment

    The company maintains one of the strongest balance sheets in the industry with over ₹2,089 crores in cash. Management explicitly stated there are no current plans for a special dividend, as the priority is to deploy this capital into high-ROI business expansions like the Dahej greenfield project and potential entries into semiconductor or pharma chemicals.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.